Michael C Honigberg1,2, Amy A Sarma3,4. 1. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 2. Harvard Medical School, Boston, MA, USA. 3. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. asarma1@partners.org. 4. Harvard Medical School, Boston, MA, USA. asarma1@partners.org.
Abstract
PURPOSE OF REVIEW: To educate clinicians on cardiovascular considerations and management strategies surrounding pregnancy in childhood cancer survivors. RECENT FINDINGS: With advances in oncologic treatment, growing numbers of childhood cancer survivors are now able to consider pregnancy. A significant proportion of survivors have received cardiotoxic therapy, particularly anthracyclines, and/or chest radiation. Cardiomyopathy is the most common cardiac complication of cancer-directed therapy; pericardial disease, valvular disease, premature coronary artery disease, and conduction abnormalities are other potential sequelae. In female survivors of childhood malignancy, cardiac evaluation should be performed prior to pregnancy as subclinical disease has the potential to be unmasked by the hemodynamic stress of pregnancy. However, limited data exist on pregnancy outcomes after cancer survivorship. With appropriate management, maternal and fetal outcomes in pregnancy following childhood cancer are generally favorable. Further research is needed to understand the incidence of cardiac complications among childhood cancer survivors, strategies to prevent these complications, optimal cardiovascular management during pregnancy and the postpartum period, and on the impact of pregnancy itself on the natural history of treatment-related cardiotoxicity.
PURPOSE OF REVIEW: To educate clinicians on cardiovascular considerations and management strategies surrounding pregnancy in childhood cancer survivors. RECENT FINDINGS: With advances in oncologic treatment, growing numbers of childhood cancer survivors are now able to consider pregnancy. A significant proportion of survivors have received cardiotoxic therapy, particularly anthracyclines, and/or chest radiation. Cardiomyopathy is the most common cardiac complication of cancer-directed therapy; pericardial disease, valvular disease, premature coronary artery disease, and conduction abnormalities are other potential sequelae. In female survivors of childhood malignancy, cardiac evaluation should be performed prior to pregnancy as subclinical disease has the potential to be unmasked by the hemodynamic stress of pregnancy. However, limited data exist on pregnancy outcomes after cancer survivorship. With appropriate management, maternal and fetal outcomes in pregnancy following childhood cancer are generally favorable. Further research is needed to understand the incidence of cardiac complications among childhood cancer survivors, strategies to prevent these complications, optimal cardiovascular management during pregnancy and the postpartum period, and on the impact of pregnancy itself on the natural history of treatment-related cardiotoxicity.
Authors: Giuseppe Curigliano; Daniela Cardinale; Susan Dent; Carmen Criscitiello; Olexiy Aseyev; Daniel Lenihan; Carlo Maria Cipolla Journal: CA Cancer J Clin Date: 2016-02-26 Impact factor: 508.702
Authors: Elvira C van Dalen; Helena J H van der Pal; Cor van den Bos; Wouter E M Kok; Huib N Caron; Leontien C M Kremer Journal: Eur J Cancer Date: 2006-08-17 Impact factor: 9.162
Authors: Hui-Ming Chang; Rohit Moudgil; Tiziano Scarabelli; Tochukwu M Okwuosa; Edward T H Yeh Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: Vera Regitz-Zagrosek; Carina Blomstrom Lundqvist; Claudio Borghi; Renata Cifkova; Rafael Ferreira; Jean-Michel Foidart; J Simon R Gibbs; Christa Gohlke-Baerwolf; Bulent Gorenek; Bernard Iung; Mike Kirby; Angela H E M Maas; Joao Morais; Petros Nihoyannopoulos; Petronella G Pieper; Patrizia Presbitero; Jolien W Roos-Hesselink; Maria Schaufelberger; Ute Seeland; Lucia Torracca Journal: Eur Heart J Date: 2011-08-26 Impact factor: 29.983
Authors: Petra Temming; Amrana Qureshi; Juliane Hardt; Alison D Leiper; Gillian Levitt; Phillip J Ancliff; David K H Webb Journal: Pediatr Blood Cancer Date: 2011-04 Impact factor: 3.167
Authors: Paul A Heidenreich; Steven L Hancock; Byron K Lee; Carol S Mariscal; Ingela Schnittger Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094